Prevalence, Treatment Pattern and Resource Use in Patients with Mixed Dyslipidemia Using Lipid Modifying Agents in Korea (PRIMULA): An Observational Study.
10.12997/jla.2016.5.2.121
- Author:
Chan Seok PARK
1
;
Hyo Soo KIM
;
Sang Hak LEE
;
Ki Hoon HAN
;
Sang Hyun KIM
;
Doo Il KIM
;
Moon Kyu LEE
;
Ji Dong SUNG
;
Young Keun AHN
;
Jae Hyeong PARK
;
Sang Hong BAEK
Author Information
1. Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea. whitesh@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Dyslipidemias;
LDL Cholesterol;
HDL Cholesterol;
Triglyderide;
Primary care
- MeSH:
Absorption;
Cardiovascular Diseases;
Cholesterol;
Cholesterol, HDL;
Cholesterol, LDL;
Dyslipidemias*;
Fibric Acids;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Korea*;
Lipoproteins;
Observational Study*;
Prevalence*;
Primary Health Care;
Retrospective Studies;
Risk Factors;
Therapeutic Uses;
Triglycerides
- From:Journal of Lipid and Atherosclerosis
2016;5(2):121-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Limited information is available on the effectiveness of lipid-modifying therapy (LMT) for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) in the Korean population. The objective of this study was to describe the prevalence of different types of lipid disorders in Korean patients using LMT. METHODS: Eight hundred seventy-one dyslipidemia patients, who were LMT-naive for >1 year prior to retrospective enrollment, were included for analysis. Serum levels of LDL-C, HDL-C, TG and total cholesterol (TC) were assessed after >1 year of LMT. We also analyzed the therapeutic effects of LMT in the subjects with high cardiovascular risk factors (n=629), atherosclerotic cardiovascular disease (ASCVD) (n=296) or diabetes without ASCVD (n=316). RESULTS: The rates of elevated LDL-C without other abnormal lipids levels, elevated TG or decreased HDL-C (with normal LDL-C levels) and high LDL-C combined with elevated TG and/or decreased HDL-C were 33.4%, 13.0% and 53.6%, respectively. After at least one year on LMT (statin alone: 81%, statin and cholesterol absorption inhibitor: 10%, fibrates alone: 3%, others: 3%), 61% of patients had at least one lipid abnormality, with 3.4% failing to reach the therapeutic LDL-C target level or a normal level of HDL-C and TG. After LMT, 64.9% of patients with high cardiovascular risk factors, 64.5% of those with ASCVD or and 64.2% of those with diabetes without ASCVD also had at least one lipid abnormality. CONCLUSION: Approximately two-thirds of patients did not reach the target or normal lipid profile after taking LMT, irrespective of combining disease and high cardiovascular risk factors. Tight lipid control is required, especially in patients with dyslipidemia and high cardiovascular risk factors or comorbid diseases.
